Live price temporarily unavailable.
Acrivon Therapeutics (ACRV) is a Health Care company. Latest news and coverage below.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Operating income | −$16.2M | −$32.7M | −$67.1M | −$89.2M | −$84.1M |
| Net income | −$16.2M | −$31.2M | −$60.4M | −$80.6M | −$77.9M |
| EPS (diluted) | −$9.32 | −$7.56 | −$2.74 | −$2.38 | −$2.02 |
| Balance sheet | |||||
| Cash and equivalents | $99.6M | $29.5M | $36.0M | $39.8M | $41.5M |
| Total assets | $106.6M | $181.2M | $138.3M | $196.6M | $129.7M |
| Total liabilities | $7.88M | $10.8M | $17.1M | $19.8M | $17.2M |
| Shareholders' equity | −$23.8M | $170.5M | $121.2M | $176.8M | $112.5M |
| Cash flow | |||||
| Operating cash flow | −$14.0M | −$30.1M | −$42.6M | −$65.7M | −$63.7M |
| Capital expenditure | $238.0K | $2.17M | $1.29M | $2.77M | $1.67M |
| Free cash flow | −$14.2M | −$32.3M | −$43.9M | −$68.4M | −$65.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$25.1M | −$25.0M | −$21.7M | −$22.6M | −$19.7M | −$20.1M | −$19.9M | −$18.7M |
| Net income | −$22.4M | −$22.8M | −$19.7M | −$21.0M | −$18.2M | −$19.0M | −$19.0M | −$18.0M |
| EPS (diluted) | −$0.59 | −$0.54 | −$0.51 | −$0.55 | −$0.47 | −$0.49 | −$0.49 | −$0.43 |
| Balance sheet | ||||||||
| Cash and equivalents | $43.4M | $39.8M | $39.2M | $41.9M | $35.4M | $41.5M | $34.1M | $41.4M |
| Total assets | $214.7M | $196.6M | $176.3M | $158.6M | $145.3M | $129.7M | $107.8M | $99.1M |
| Total liabilities | $17.8M | $19.8M | $16.0M | $15.5M | $16.7M | $17.2M | $12.3M | $12.4M |
| Shareholders' equity | $196.9M | $176.8M | $160.4M | $143.0M | $128.6M | $112.5M | $95.5M | $86.7M |
| Cash flow | ||||||||
| Operating cash flow | −$17.3M | −$17.4M | −$19.5M | −$16.6M | −$12.3M | −$15.2M | −$20.5M | −$14.9M |
| Capital expenditure | $989.0K | $827.0K | $58.0K | $493.0K | $899.0K | $219.0K | $14.0K | $87.0K |
| Free cash flow | −$18.3M | −$18.2M | −$19.6M | −$17.1M | −$13.2M | −$15.5M | −$20.6M | −$14.9M |
From Acrivon Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Acrivon Therapeutics in our feed yet.